CheckMate914
Por um escritor misterioso
Descrição
Ziad Bakouny, MD, MSc on X: Dr. @motzermd with an important presentation of #CHECKMATE914 Part A subgroup analyses. @ASCO #ASCO23 While the overall trial showed no improved outcomes with the combination of
Adjuvant nivolumab plus ipilimumab (NIVO+IPI) vs placebo (PBO) for localized renal cell carcinoma (RCC) at high risk of relapse after nephrectomy: Results from the randomized, phase III CheckMate 914 trial - UROONCO
Immunotherapy combo fails to extend disease-free survival in high-risk kidney cancer
Toni Choueiri, MD on X: Masterful presentation by @motzermd reporting subgroup analyses from #CheckMate914 (part A). Exploratory analyses suggest tumor PD-L1 expression influenced outcome of adjuvant IPI+NIVO in pts with localized #RCC
Cancers, Free Full-Text
PDF) Optimal Choice of Adjuvant Treatment for Renal Cell Carcinoma Following Nephrectomy
옵디보, '신세포암'에서 희비 교차 < 암/혈액/희귀/소아청소년 < 암/혈액/희귀/소아청소년 < 학술 < 기사본문 - 메디칼업저버
CheckMate 914: Nivolumabe adjuvante mais ipilimumabe no tratamento do carcinoma de células renais localizado com alto risco de recidiva - Oncologia Brasil
.png)
ASCO热评丨盛锡楠教授：肾癌领域治疗进展-肿瘤瞭望
